Caribou Biosciences (CRBU) Competitors $1.87 +0.00 (+0.21%) As of 09:30 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRBU vs. ABUS, GHRS, KALV, KURA, SIGA, BCAX, VIR, RLAY, KROS, and MGTXShould you be buying Caribou Biosciences stock or one of its competitors? The main competitors of Caribou Biosciences include Arbutus Biopharma (ABUS), GH Research (GHRS), KalVista Pharmaceuticals (KALV), Kura Oncology (KURA), Siga Technologies (SIGA), Bicara Therapeutics (BCAX), Vir Biotechnology (VIR), Relay Therapeutics (RLAY), Keros Therapeutics (KROS), and MeiraGTx (MGTX). These companies are all part of the "pharmaceutical products" industry. Caribou Biosciences vs. Its Competitors Arbutus Biopharma GH Research KalVista Pharmaceuticals Kura Oncology Siga Technologies Bicara Therapeutics Vir Biotechnology Relay Therapeutics Keros Therapeutics MeiraGTx Caribou Biosciences (NASDAQ:CRBU) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings. Which has better valuation & earnings, CRBU or ABUS? Arbutus Biopharma has lower revenue, but higher earnings than Caribou Biosciences. Arbutus Biopharma is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCaribou Biosciences$9.99M17.47-$149.10M-$1.78-1.05Arbutus Biopharma$6.17M119.12-$69.92M-$0.29-13.22 Do analysts rate CRBU or ABUS? Caribou Biosciences currently has a consensus target price of $6.67, suggesting a potential upside of 255.75%. Arbutus Biopharma has a consensus target price of $5.50, suggesting a potential upside of 43.45%. Given Caribou Biosciences' higher possible upside, analysts plainly believe Caribou Biosciences is more favorable than Arbutus Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Caribou Biosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Arbutus Biopharma 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, CRBU or ABUS? Caribou Biosciences has a beta of 2.54, suggesting that its share price is 154% more volatile than the S&P 500. Comparatively, Arbutus Biopharma has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Is CRBU or ABUS more profitable? Arbutus Biopharma has a net margin of -352.24% compared to Caribou Biosciences' net margin of -1,800.93%. Arbutus Biopharma's return on equity of -59.28% beat Caribou Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Caribou Biosciences-1,800.93% -62.35% -49.65% Arbutus Biopharma -352.24%-59.28%-44.11% Do insiders & institutionals hold more shares of CRBU or ABUS? 77.5% of Caribou Biosciences shares are owned by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are owned by institutional investors. 9.5% of Caribou Biosciences shares are owned by insiders. Comparatively, 20.3% of Arbutus Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media refer more to CRBU or ABUS? In the previous week, Arbutus Biopharma had 1 more articles in the media than Caribou Biosciences. MarketBeat recorded 1 mentions for Arbutus Biopharma and 0 mentions for Caribou Biosciences. Arbutus Biopharma's average media sentiment score of 1.23 beat Caribou Biosciences' score of 0.94 indicating that Arbutus Biopharma is being referred to more favorably in the news media. Company Overall Sentiment Caribou Biosciences Positive Arbutus Biopharma Positive SummaryArbutus Biopharma beats Caribou Biosciences on 10 of the 15 factors compared between the two stocks. Get Caribou Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CRBU and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRBU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRBU vs. The Competition Export to ExcelMetricCaribou BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$174.14M$3.10B$5.77B$9.76BDividend YieldN/A2.28%6.66%4.49%P/E Ratio-1.0520.8683.0526.39Price / Sales17.47391.41527.23108.99Price / CashN/A43.5325.7028.92Price / Book1.058.1011.006.58Net Income-$149.10M-$53.35M$3.28B$265.84M7 Day Performance-5.35%-0.29%-0.19%-0.26%1 Month Performance-3.90%9.18%8.33%5.82%1 Year Performance-5.35%10.11%53.31%22.47% Caribou Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRBUCaribou Biosciences2.4674 of 5 stars$1.87+0.2%$6.67+255.7%-13.0%$174.14M$9.99M-1.05100ABUSArbutus Biopharma2.5768 of 5 stars$3.50-2.5%$5.50+57.1%-1.3%$688.20M$6.17M-12.0790News CoveragePositive NewsGHRSGH Research1.7311 of 5 stars$13.18+0.8%$32.00+142.8%+32.7%$680.53MN/A-17.8110News CoverageKALVKalVista Pharmaceuticals3.9402 of 5 stars$12.99-3.1%$26.29+102.4%+6.7%$675.06MN/A-3.52100Positive NewsUpcoming EarningsKURAKura Oncology3.85 of 5 stars$7.65flat$24.10+215.0%-62.3%$664M$53.88M-3.38130News CoveragePositive NewsSIGASiga Technologies2.3555 of 5 stars$8.70-4.7%N/A-4.4%$653.76M$138.72M7.7040News CoverageBCAXBicara TherapeuticsN/A$11.32-4.4%$32.25+184.9%N/A$646.02MN/A-3.5732Positive NewsVIRVir Biotechnology3.2243 of 5 stars$4.38-4.4%$30.25+590.6%-39.5%$636.24M$74.21M-1.10580Positive NewsRLAYRelay Therapeutics2.1725 of 5 stars$3.51-4.9%$17.25+391.5%-46.1%$636.20M$8.36M-1.80330KROSKeros Therapeutics3.6325 of 5 stars$14.76-5.1%$30.00+103.3%-65.3%$631.97M$232.84M47.61100Positive NewsMGTXMeiraGTx4.4957 of 5 stars$7.58-3.2%$24.00+216.6%+79.4%$629.90M$33.28M-3.72300News CoveragePositive News Related Companies and Tools Related Companies Arbutus Biopharma Competitors GH Research Competitors KalVista Pharmaceuticals Competitors Kura Oncology Competitors Siga Technologies Competitors Bicara Therapeutics Competitors Vir Biotechnology Competitors Relay Therapeutics Competitors Keros Therapeutics Competitors MeiraGTx Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRBU) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Caribou Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Caribou Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRBU Stock Alerts